Nifty 50
- Bajaj Auto₹10,077299.00 (3.06%)
- Tech Mahindra₹1,469.60-44.50 (-2.94%)
- Dr. Reddy's Labs₹1,226.5029.50 (2.46%)
- ITC₹258.70-7.30 (-2.74%)
- Mahindra & Mahindra₹2,830.6034.40 (1.23%)
- Bharti Airtel₹1,767.70-37.40 (-2.07%)
- Eicher Motors₹7,11868.00 (0.96%)
- SBI₹939.55-19.55 (-2.04%)
- BSE₹3,316.8029.60 (0.90%)
- NTPC₹306.25-5.75 (-1.84%)
- Bharat Electronics₹370.702.55 (0.69%)
- Hindustan Unilever₹1,826.30-30.40 (-1.64%)
- HDFC Life Insurance ₹560.403.75 (0.67%)
- Coal India₹404.95-6.60 (-1.60%)
- JSW Steel₹1,173.505.50 (0.47%)
- L&T₹3,645.60-57.70 (-1.56%)
- Eternal₹324.901.45 (0.45%)
- ICICI Bank₹1,335.50-19.50 (-1.44%)
- Trent₹2,930.8012.60 (0.43%)
- Nestle₹1,320.80-12.20 (-0.92%)
- Offerings
- Tools & Platforms
Tools & Calculators
- Open API
- Calculators
- SIP Calculator
- CAGR Calculator
- Compound Interest Calculator
- FD Calculator
- RD Calculator
- EPF Calculator
- Retirement Calculator
- HDFC SIP Calculator
- Mutual Fund Return Calculator
- Lumpsum Calculator
- Step Up SIP Calculator
- ETF SIP Calculator
- Brokerage Calculator
- Equity Margin Calculator
- SWP Calculator
- EMI Calculator
- MTF Calculator
- Margin Pledge Calculator
- Algo Strategy
- Markets
Stocks
F&O
Mutual Funds
- More
Jubilant Pharmova Q1 Net Profit Down 45% at Rs 56.4 Cr
Authored By PTI | Published at: Aug 11, 2026 09:45 AM IST

Open Free Demat Account
Open Free Demat Account
New Delhi: Jubilant Pharmova Ltd on Monday reported a 45 per cent decline in consolidated net profit at Rs 56.4 crore in the first quarter ended June, hit by higher expenses and depreciation.
The company had posted a consolidated net profit of Rs 102.5 crore in the corresponding quarter last fiscal, Jubilant Pharmova Ltd said in a regulatory filing.
Consolidated total revenue from operations in Q1 FY27 stood at Rs 2,229.4 crore, up from Rs 1,900.7 crore in the year-ago period, it added.
Total expenses in the quarter under review stood higher at Rs 2,162.9 crore, compared to Rs 1,758.2 crore in the same period last fiscal, the company said.
Commenting on the performance, in a joint statement, Shyam S Bhartia, Chairman, and Hari S Bhartia, Co-Chairman & Non-Executive Director, Jubilant Pharmova Ltd, said, “Revenue growth is broad-based across all our business segments, but particularly strong in contract development and manufacturing of sterile injectables on the back of technology transfer revenues from the new and third line.” PAT margins in the first quarter decreased due to lower operating profitability and higher depreciation, they added.
(Disclaimer: Except for the headline, this article has not been edited by HDFC Sky editorial team and is auto-generated from PTI feed.)
Disclaimer
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please Note: The information shared is intended solely for informational purposes and does not make any investment recommendations
Disclaimer
At HDFC SKY*, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please Note: The information shared is intended solely for informational purposes and does not make any investment recommendations.
HDFC SKY from HDFC Securities, one of most trusted trading platforms in India, has been recognized with the *Next-Gen Digi Content Awards 2025-26.
Open Free Demat Account
Open Free Demat Account
₹910.60





By signing up I certify terms, conditions & privacy policy
Join Us
Add as preferred source on Google







